| 000 | 01753 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250518031026.0 | ||
| 264 | 0 | _c20200615 | |
| 008 | 202006s 0 0 eng d | ||
| 022 | _a2473-4276 | ||
| 024 | 7 |
_a10.1200/CCI.18.00097 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHwang, Jessica P | |
| 245 | 0 | 0 |
_aCost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy. _h[electronic resource] |
| 260 |
_bJCO clinical cancer informatics _c03 2019 |
||
| 300 |
_a1-12 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDecision Making |
| 650 | 0 | 4 | _aDecision Trees |
| 650 | 0 | 4 |
_aHepatitis B _xdiagnosis |
| 650 | 0 | 4 |
_aHepatitis B virus _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadverse effects |
| 650 | 0 | 4 | _aMass Screening |
| 650 | 0 | 4 | _aModels, Theoretical |
| 650 | 0 | 4 |
_aNeoplasms _xcomplications |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 | _aSEER Program |
| 700 | 1 | _aHuang, Danmeng | |
| 700 | 1 | _aVierling, John M | |
| 700 | 1 | _aSuarez-Almazor, Maria E | |
| 700 | 1 | _aShih, Ya-Chen Tina | |
| 700 | 1 | _aChavez-MacGregor, Mariana | |
| 700 | 1 | _aDuan, Zhigang | |
| 700 | 1 | _aGiordano, Sharon H | |
| 700 | 1 | _aHershman, Dawn L | |
| 700 | 1 | _aFisch, Michael J | |
| 700 | 1 | _aCantor, Scott B | |
| 773 | 0 |
_tJCO clinical cancer informatics _gvol. 3 _gp. 1-12 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/CCI.18.00097 _zAvailable from publisher's website |
| 999 |
_c29498514 _d29498514 |
||